- Home
- DJCO vs VSTM Comparison
DJCO vs VSTM Comparison
Compare DJCO & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DJCO | VSTM |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.5M | 581.6M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | DJCO | VSTM |
|---|---|---|
| Price | $477.30 | $10.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | 308.8K | ★ 2.1M |
| Earning Date | 12-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 115.36 | N/A |
| EPS | ★ 70.22 | N/A |
| Revenue | ★ $79,159,000.00 | $13,379,000.00 |
| Revenue This Year | N/A | $183.10 |
| Revenue Next Year | N/A | $271.39 |
| P/E Ratio | $6.56 | ★ N/A |
| Revenue Growth | 10.54 | ★ 33.79 |
| 52 Week Low | $348.63 | $3.46 |
| 52 Week High | $596.60 | $11.25 |
Technical Indicators
Market Signals| Indicator | DJCO | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 60.78 | 55.73 |
| Support Level | $422.82 | $9.95 |
| Resistance Level | $501.66 | $10.70 |
| Average True Range (ATR) | 29.25 | 0.56 |
| MACD | 4.49 | 0.02 |
| Stochastic Oscillator | 83.41 | 59.05 |
Price Performance
Historical ComparisonAbout DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.